Skip to main content

Table 1 Bias evaluation of included studies

From: Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review

Study ID Author Domains Reviewers observations
Random sequence generation Allocation Blinding Participants and people blinding Evaluators and outcome blinding Incomplete outcome data
Method described with detail Investigative personnel was blind to allocation Blinding method for participants and personnel was effective? Blinding method for the study evaluators was effective? Main outcomes, fall outs, exclusions, number, in each intervention group, reason for losses and changes in plan analysis
1 Maurer et al., 2011 [20] Random sequence by validated system 1:1 Similar packages and presentation between placebo and intervention Yes Yes Yes -
2 Saini et al., 2011 [21] Sequence 1:1:1:1 Similar packages and presentation between placebo and intervention Yes Yes Yes -
3 Maurer et al., 2013 [19] Sequence 1:1:1:1 by voice interactive service Similar packages and presentation between placebo and intervention Yes Yes Yes Blind in each center, drug not blinded but person administering the drug is blinded
4 Kaplan et al., 2013 [22] 3:1 stratified by itch severity score (ISS) and baseline weight Similar packages and presentation between placebo and intervention Yes Yes Yes Person who prepared the drug was not blinded, but the one administering the drug was blinded
5 Saini et al., 2014 [23] Sequence 1:1:1:1 stratified by weekly ISS, baseline weight (< or ?80 kg) and study center by interactive voice and web response system Not specified in the article but the clinicaltrials.gov register specified the similar packages between placebo and intervention Yes Yes Yes Person who prepared the drug was not blinded but did not interact with patients